Also, 64 Non-Hispanic Blacks (41%) died within 1 year of their first specimen collection date compared to 92 Non-Hispanic Whites (23.3%). Non-Hispanic Blacks with CP-CRE who died within 1 year had a mortality rate of 5.6 per 100,000 (95% CI, 4.21–6.94) Black population, which was 1.6 times higher than Non-Hispanic White persons at 3.5 per 100,000 (95% CI, 2.94–3.95; χ^2 $P < .001$) White population. **Conclusions:** Despite a lower mean age, non-Hispanic Black CP-CRE cases had a higher 1-year mortality rate than non-Hispanic Whites. Racial and ethnicity data often are missing or incomplete from surveillance data. Data linkages can be a valuable tool to gather additional clinical and demographic data that may be missing from public health surveillance data to improve our understanding of health disparities. Recognition of these health disparities among CRE can provide an opportunity for public health to create more targeted interventions and educational outreach.

Funding: None
Disclosures: None

Antimicrobial Stewardship & Healthcare Epidemiology 2022;2(Suppl. S1):s64–s65

doi:10.1017/ash.2022.181

Presentation Type:
Poster Presentation - Poster Presentation
Subject Category: Surveillance/Public Health

Developing national benchmarks for antimicrobial resistance—NHSN, 2019

Hsiu Wu; Erin O'Leary; Minn Soe and Jonathan Edwards

Background: The emergence and spread of drug-resistant pathogens continues to significantly impact patient safety and healthcare systems. Although antimicrobial susceptibility test (AST) results of clinical specimens are used by individual facilities for antimicrobial resistance surveillance, accurate tracking and benchmark comparison of a facility's antimicrobial resistance using national data requires risk-adjusted methods to be more meaningful. The CDC NHSN Antimicrobial Resistance (AR) Option collects patient-level, deduplicated, isolate information, including AST results, for >20 organisms from cerebrospinal fluid, lower respiratory tract (LRT), blood, and urinary specimens. To provide risk-adjusted national benchmarks, we developed prediction models for incidence of hospital-onset isolates with antimicrobial resistance. **Methods:** We analyzed AST results of isolates reported through the NHSN AR Option for January through December 2019. Isolates from facilities that had >10% missing AST results for the organism-drug combinations or from hospitals that used outdated breakpoints were excluded. We assessed associations between facility-level factors and incidence rates of hospital-onset (specimen collected 3 days or more after hospital admission) isolates of specific drug-resistant phenotypes from blood, LRT, and urinary specimens. Factors included number of beds, length of stay, and prevalence of community onset isolates of the same phenotype. Drug-resistant phenotypes assessed included methicillin-resistant *Staphylococcus aureus* (MRSA), multidrug-resistant (MDR) *Pseudomonas aeruginosa*, carbapenem-resistant Enterobacterales (CRE), fluoroquinolone-resistant *Pseudomonas aeruginosa*, fluoroquinolone-resistant Enterobacterales, and extended-spectrum cephalosporin-resistant Enterobacterales. Isolates of different phenotypes and from different specimen sources were modeled separately. Negative binomial regression was used to evaluate the factors associated with antimicrobial resistance incidence. Variable entry into the models is based on significance level P Among the models, 1 for each drug-resistant phenotype-specimen type combination, the number of isolates with AST results ranged from 718 (*Pseudomonas aeruginosa*—fluoroquinolones, blood) to 16,412 (Enterobacterales—fluoroquinolones, urine). The pooled incidence rate was highest for fluoroquinolone-resistant Enterobacterales in urinary specimens (0.2179 isolates per 1,000 patient days) among all phenotype-specimen combinations evaluated (Table 1). The incidence of drug-resistant isolates was consistently associated with community-onset prevalence across models evaluated. Other associated factors varied across phenotype-specimen combinations (Table 2). **Conclusions:** We developed statistical models to predict facility-level incidence rates of hospital-onset antimicrobial resistant isolates based on community-onset drug-resistant prevalence and facility characteristics. These models will enable facilities to compare antimicrobial resistance rates to the national benchmarks and therefore to inform their antimicrobial stewardship and infection prevention efforts.

Table 1: Incidence of hospital-onset resistant isolates, by specimen type

Drug-resistant phenotype	Specimen type	Number of facilities in analysis dataset	Number of drug resistant isolates	Number of tested isolates	Pooled resistant isolate rate, per 1000 patient-days	Resistant isolate rate per 1000 patient-days, Median(Q1-Q3)
Pseudomonas aeruginosa-Fluoroquinolones	Blood	184	114	718	0.0074	0(0-0.012)
	LRT	296	1307	5640	0.0688	0.039(0-0.083)
	Urine	294	535	3092	0.0281	0.016(0-0.044)
Pseudomonas aeruginosa - Multidrug	Blood	191	96	783	0.0059	0(0-0.007)
	LRT	306	1084	6109	0.0534	0.027(0-0.067)
	Urine	316	329	3383	0.0158	0(0-0.022)
Enterobacterales[a]- Fluoroquinolones	Blood	274	907	3130	0.0488	0.0240(0-0.050)
	LRT	289	1255	7089	0.0677	0.043(0.015-0.088)
	Urine	344	4176	16412	0.2179	0.166(0.0845-0.0264)
Staphylococcus aureus-Methicillin	Blood	285	971	2330	0.0501	0.04(0.018-0.067)
	LRT	308	3865	7856	0.1910	0.16(0.085-0.242)
	Urine	207	312	599	0.0193	0.018(0-0.033)
Enterobacterales[a]- Carbapenem	Blood	181	91	2370	0.0070	0(0-0)
	LRT	203	190	5641	0.0136	0(0-0.015)
	Urine	241	168	12596	0.0117	0(0-0.009)
Enterobacterales[a]- Extended-spectrum cephalosporin	Blood	237	873	3036	0.0451	0.027(0-0.052)
	LRT	242	1837	7017	0.1091	0.077(0.031-0.127)
	Urine	291	3165	15246	0.1814	0.125(0.057-0.207)

a. Enterobacterales defined as E. coli, Klebsiella pneumoniae, K. oxytoca, and Enterobacter isolates
b. LRT: lower respiratory tract, Number of ICU beds: Number of beds in intensive care units (ICU), Number of beds: Number of hospital beds, ICU percent: Percentage of hospital beds in ICU among all hospital beds, Antibiotic test: Indicator of whether susceptibility testing is done onsite or offsite, Community-onset prevalence: Prevalence of community onset isolates of the same phenotype (per 10,000 admissions), this variable is relevant for hospital onset resistance infection model

Table 2: Risk-adjustment summary for hospital-onset antimicrobial resistant isolates

Drug-resistant phenotype	Specimen type	Community-onset prevalence	Hospital length of stay	Number of beds	Number of ICU beds	ICU percent	Facility type	Medical affiliation	Medical type
Pseudomonas aeruginosa-Fluoroquinolones	Blood	✓							
	LRT	✓		✓					
	Urine	✓							
Pseudomonas aeruginosa - Multidrug	Blood	✓							
	LRT	✓			✓				
	Urine	✓	✓						
Enterobacterales[a]- Fluoroquinolones	Blood	✓	✓	✓					
	LRT	✓		✓					
	Urine	✓	✓						
Staphylococcus aureus-Methicillin	Blood	✓	✓		✓				
	LRT	✓	✓						
	Urine	✓				✓			
Enterobacterales[a]- Carbapenem	Blood	✓							
	LRT	✓	✓						
	Urine	✓	✓						
Enterobacterales[a]- Extended-spectrum cephalosporin	Blood	✓	✓						
	LRT	✓		✓					
	Urine	✓	✓						

a. Enterobacterales defined as E. coli, Klebsiella pneumoniae, K. oxytoca, and Enterobacter isolates
b. LRT: lower respiratory tract, Number of ICU beds: Number of beds in intensive care units (ICU), Number of beds: Number of hospital beds, ICU percent: Percentage of hospital beds in ICU among all hospital beds, Antibiotic test: Indicator of whether susceptibility testing is done onsite or offsite, Community-onset prevalence: Prevalence of community onset isolates of the same phenotype (per 10,000 admissions), this variable is relevant for hospital onset resistance infection model

Funding: None
Disclosures: None

Antimicrobial Stewardship & Healthcare Epidemiology 2022;2(Suppl. S1):s65

doi:10.1017/ash.2022.182

Presentation Type:
Poster Presentation - Poster Presentation
Subject Category: Surveillance/Public Health

Findings from healthcare-associated infections data validation attestation in California general acute-care hospitals

Nadia Barahmani; Andrea Parriott; Erin Epson; Genie Tang and N. Neely Kazerouni

Background: Accurate and complete hospital healthcare-associated infection (HAI) data are essential to inform facility-level HAI prevention efforts and to ensure the validity and reliability of annual public reports. We implemented a validation attestation survey to assess and improve the HAI data reported by California hospitals via NHSN. **Methods:** The California Department of Public Health (CDPH) HAI Program invited all 401 general acute-care hospitals in California to participate in an annual HAI validation attestation survey in 2021. The survey was designed to be completed by the person with primary responsibility for HAI surveillance and reporting consistent with NHSN protocols and California laws. Survey questions addressed HAI reporting knowledge and practices and surgical procedures performed, and they included 3 hypothetical scenarios evaluating hospital application of HAI surveillance, decision making, and reporting methods. **Results:** We received responses from 345 hospitals (86%). For the 3 hypothetical scenarios, 171 hospitals (49.6%) correctly answered all 3 questions, 110 hospitals (31.9%) answered 2 questions correctly, 52 (15.1%) hospitals answered 1 question correctly, and 12 hospitals (3.5%) answered zero questions correctly. We did not detect a statistically